Gilead
Gilead’s CFO and Executive Vice President to depart in 2020
May 7, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma
Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, …
Top Ten most popular articles on Pharmafile.com this week!
May 3, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, Gilead, autism, dementia, opioids, pharma
This week was marked by the failure of two Phase 3 trials after both Eli Lilly and Gilead suffered from …
Gilead’s CFO and Executive Vice President to depart in 2020
May 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma
Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, …
Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland
April 29, 2019Manufacturing and Production, Sales and Marketing CAR-T, Gilead, Manufacturing Facility, Maryland, kite pharma
Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US). …
Gilead’s selonsertib crashes at Phase 3 in NASH
April 26, 2019Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib
Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …
Top Ten most popular articles on Pharmafile.com this week!
April 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Genentech, Gilead, HIV, MS, Novartis, kidney disease, pharma
This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK …
Top Ten most popular articles on Pharmafile.com this week!
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior
This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …
Gilead to lay off one fifth of sales force
April 11, 2019Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales
Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents …
Gilead accused of ripping off US taxpayers
March 28, 2019Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents
Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …
Top Ten most popular articles on Pharmafile.com this week!
March 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10
HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …
Gilead’s Biktarvy maintains HIV suppression for 48 weeks in children and adolescents
March 7, 2019Research and Development Biktarvy, Gilead, HIV, pharma
Gilead has lifted the curtain on new Phase 2/3 efficacy data for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 …
Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland
February 12, 2019Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma
It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …
Gilead shares drop 4% after failure of NASH drug to meet primary endpoint
February 12, 2019Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib
Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …
Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus
December 21, 2018Medical Communications Agenus, Gilead, Lexington, Massachusetts, USA, immuno-oncology, oncology
California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on …
Gilead and Scholar Rock collaborate on fibrosis in deal worth more than $80m
December 20, 2018Business Services, Research and Development Califonia, Gilead, Scholar Rock, USA, fibrosis
California-based antiviral drugs specialist Gilead Sciences has entered into a strategic partnership with Cambridge, Massachusetts-based biotech Scholar Rock as part …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
